DDrare: Database of Drug Development for Rare Diseases

43. 顕微鏡的多発血管炎
［臨床試験数：85，薬物数：80（DrugBank：19），標的遺伝子数：13，標的パスウェイ数：85］

Searched query = "Microscopic polyangiitis", "MPA"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 5009111000001105; Alemtuzumab; Avacopan; Azathioprine; BELIMUMAB; Belimumab; Belimumab 10 mg/kg; Benlysta; Benlysta 400 mg powder for concentrate for solution for infusion; Benlysta 400mg polvere per concentrato per soluzione per infusione; Blisibimod; CCX168; CELLCEPT; CYCLOPHOSPHAMIDE; CellCept (mycophenolate mofetil); Cellcept; Chimeric monoclonal antibody, IgG4 subtype; Corticosteroid; Corticosteroid and azathioprine; Cyclophosphamide; Cyclophosphamide, Azathioprine,prednisone,methylprednisolone; DELTACORTENE; ENDOXAN BAXTER; Endoxan; Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS); GALEN® tablet; Glucocorticoid (GC); Glucocorticoids; Glucocorticoids (GC); Glucocorticoids - Reduced Dose; Glucocorticoids - Standard Dose; Glucocorticoids [Reduced Dose]; Glucocorticoids [Standard Dose]; Human normal immunoglobulin; Hydroxychloroquine; IFX-1; Infliximab; Intravenous immunoglobulins (human immunoglobulins G); Intravenous methyl prednisolone; MabThera; MabThera®; MabThera® 100MG; MabThera® 500MG; Methotrexate; Methyl prednisolone; Methylprednisolone; Methylprednisolone (or other glucocorticoid); Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; Mycophenolate mofetil,methotrexate; Mycophenolic acid; Naltrexone; Naltrexone Hydrochloride; Other: No Plasma Exchange; PREDNISONE; Pednisone; Placebo (physiological saline); Plaquenil - Hydroxychloroquine 200mg Film coated tablets; PredniSONE Tablets, USP; Prednisolone; Prednison acis® 20 mg; Prednison acis® 5 mg; Prednisone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; Procedure: Plasma Exchange; Procedure: Plasma exchange; RITUXIMAB; RIXATHON 500mg; RO0452294/V01; RO0452294/V02; Remission induction therapy; Rituximab; Rituximab (Arm A); Rituximab (Arm B); Ro106-1443; Sendoxan; Tocilizumab; Vitamin D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03482479 (ClinicalTrials.gov)	February 4, 2019	22/3/2018	Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis	Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis	Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis	Drug: Naltrexone Hydrochloride;Other: Placebo Comparator	University of Pennsylvania	NULL	Recruiting	18 Years	N/A	All	36	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03482479
(ClinicalTrials.gov)

February 4, 2019

22/3/2018

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis

Drug: Naltrexone Hydrochloride;Other: Placebo Comparator

University of Pennsylvania

NULL

Recruiting

18 Years

N/A

All

Phase 2

United States